On Jun 27, 2018 Baird Reaffirms Stock Neutral Rating on Merrimack Pharmaceuticals (NASDAQ:MACK) and $7 Target.

June 27, 2018 - By Cynthia Ashman

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Corporate Logo

Reiterated Merrimack Pharmaceuticals (NASDAQ:MACK) Rating.

Merrimack Pharmaceuticals (NASDAQ:MACK)‘s stock Neutral rating was restate by Baird on Tuesday morning. The broker’s Research analysts have a $7 target price per share and gives a potential upside of 39.17 % on the stock.

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Ratings Coverage

In total 3 analysts cover Merrimack Pharmaceuticals (NASDAQ:MACK). “Buy” rating has 0, “Sell” are 1, while 2 are “Hold”. 0 are bullish. 4 are the (NASDAQ:MACK)’s analyst reports since May 8, 2018 according to StockzIntelligence Inc. On Monday, June 25 the stock of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) has “Underweight” rating given by JP Morgan. On Monday, June 25 the rating was maintained by Cowen & Co with “Hold”. On Tuesday, June 26 the rating was maintained by Robert W. Baird with “Neutral”.

MACK touched $5.03 during the last trading session after $0.07 change.Merrimack Pharmaceuticals, Inc. has volume of 176,243 shares. Since June 27, 2017 MACK has declined 62.77% and is downtrending. The stock underperformed the S&P500 by 75.34%.

On August, 8. Investors expect Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) to publish its quarterly earnings, according to Faxor. Analysts predict 36.82 % diference or $-1.39 from the $-2.2 EPS from 2017. 4.51 % negative EPS growth is what Wall Street’s predicts after $-1.33 reported EPS last quarter.

Merrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States.The company has $67.18 million market cap. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1.0.14 is the P/E ratio. The Company’s clinical program also comprises MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to solid tumors.

For more Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) news published briefly go to: Schaeffersresearch.com, Streetinsider.com, Benzinga.com, Seekingalpha.com or Benzinga.com. The titles are as follows: “2 Pharmaceutical Stocks Touching Record Lows” published on June 25, 2018, “Ex-Akebia employee jailed for night as insider trading trial starts” on June 26, 2018, “Benzinga’s Daily Biotech Pulse: Epidiolex, Roche’s Influenza Drug Gets Priority Review Status, Xeris Jumps On …” with a publish date: June 26, 2018, “Merrimack Pharma -31% as pancreatic cancer treatment fails to meet goals” and the last “10 Biggest Price Target Changes For Tuesday” with publication date: June 26, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: